These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10349697)

  • 1. The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C.
    Younossi ZM; Perrillo RP
    Semin Liver Dis; 1999; 19 Suppl 1():95-102. PubMed ID: 10349697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial.
    Abdelmalek MF; Harrison ME; Gross JB; Poterucha JJ; Gossard AA; Spivey JR; Rakela J; Lindor KD
    J Clin Gastroenterol; 1998 Mar; 26(2):130-4. PubMed ID: 9563925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.
    Brillanti S; Levantesi F; Masi L; Foli M; Bolondi L
    Hepatology; 2000 Sep; 32(3):630-4. PubMed ID: 10960460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
    El-Zayadi AR; Attia M; Badran HM; El-Tawil A; Zalata K; Barakat E; Selim O; El-Nakeeb A; Saied A
    Liver Int; 2005 Aug; 25(4):746-51. PubMed ID: 15998425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C.
    McHutchison JG; Poynard T
    Semin Liver Dis; 1999; 19 Suppl 1():57-65. PubMed ID: 10349693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
    Maddrey WC
    Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of amantadine and other adjuvant therapies in the treatment of hepatitis C.
    Brillanti S
    Semin Liver Dis; 2004; 24 Suppl 2():89-95. PubMed ID: 15346251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients.
    Neary MP; Cort S; Bayliss MS; Ware JE
    Semin Liver Dis; 1999; 19 Suppl 1():77-85. PubMed ID: 10349695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients.
    Boucher E; Guyader D; Jacquelinet S; Andre P; Mendler MH; Turlin B; Canva V; Nousbaum JB; Bernard PH; Nouel O; Raabe JJ; Dao T; Gasser P; Verger P; Boutin J; Bergerault P; Joram F; Colmar P; Messner M; Brissot P; Deugnier Y
    Dig Liver Dis; 2000; 32(1):29-33. PubMed ID: 10975752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of interferon alfa-2a and amantadine does not improve the efficacy of interferon therapy in patients with chronic hepatitis C.
    Yang SS; Tu TC; Wu CH; Chen DS
    Hepatogastroenterology; 2003; 50(53):1575-8. PubMed ID: 14571789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
    N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standards of treatment in chronic hepatitis C.
    Gish RG
    Semin Liver Dis; 1999; 19 Suppl 1():35-47. PubMed ID: 10349691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV.
    Dieterich DT; Purow JM; Rajapaksa R
    Semin Liver Dis; 1999; 19 Suppl 1():87-94. PubMed ID: 10349696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis.
    Clerici C; Distrutti E; Gentili G; Solinas A; Miglietti M; Balò S; Giansanti M; Rusticali AG; Morselli-Labate AM; Morelli A
    Minerva Med; 1997 May; 88(5):219-25. PubMed ID: 9250283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C.
    Davis GL
    Semin Liver Dis; 1999; 19 Suppl 1():49-55. PubMed ID: 10349692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.
    Brillanti S; Foli M; Di Tomaso M; Gramantieri L; Masci C; Bolondi L
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):130-4. PubMed ID: 10363198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of interferon therapy nonresponders.
    Shiffman ML
    Clin Liver Dis; 2001 Nov; 5(4):1025-43. PubMed ID: 11685793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C.
    Mangia A; Minerva N; Annese M; Leandro G; Villani MR; Santoro R; Carretta V; Bacca D; Giangaspero A; Bisceglia M; Ventrella F; Dell'Erba G; Andriulli A
    Hepatology; 2001 Apr; 33(4):989-93. PubMed ID: 11283865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients.
    Fabbri C; Marchetto S; Pezzoli A; Accogli E; Fusaroli P; Azzaroli F; Jaboli MF; Mazzeo C; Montagnani M; Festi D; Roda E; Mazzella G
    Eur J Gastroenterol Hepatol; 2000 May; 12(5):511-5. PubMed ID: 10833093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.